Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer.
about
Human papillomavirus and cervical cancer: biomarkers for improved prevention effortsE6/E7 mRNA testing for human papilloma virus-induced high-grade cervical intraepithelial disease (CIN2/CIN3): a promising perspectiveTriage of women with minor cervical lesions: data suggesting a "test and treat" approach for HPV E6/E7 mRNA testing.HPV E6/E7 mRNA testing is more specific than cytology in post-colposcopy follow-up of women with negative cervical biopsyMassARRAY spectrometry is more sensitive than PreTect HPV-Proofer and consensus PCR for type-specific detection of high-risk oncogenic human papillomavirus genotypes in cervical cancer.HPV mRNA is more specific than HPV DNA in triage of women with minor cervical lesions.Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancerPrognostic value of HPV E6/E7 mRNA assay in women with negative colposcopy or CIN1 histology result: a follow-up study.Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA testType-specific human papillomavirus E6/E7 mRNA detection by real-time PCR improves identification of cervical neoplasia.Comparison of the Seeplex HPV4A ACE and the Cervista HPV assays for the detection of HPV in hybrid capture 2 positive media.Molecular beacons in diagnostics5-type HPV mRNA versus 14-type HPV DNA test: test performance, over-diagnosis and overtreatment in triage of women with minor cervical lesions.Comparison of the Abbott RealTime High-Risk Human Papillomavirus (HPV), Roche Cobas HPV, and Hybrid Capture 2 assays to direct sequencing and genotyping of HPV DNA.High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytologyLaboratory and clinical aspects of human papillomavirus testingHPV-based Tests for Cervical Cancer Screening and Management of Cervical Disease.Point-of-care test for cervical cancer in LMICs.Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.Stability of cervical specimens in SurePath medium for human papillomavirus testing with the Roche cobas 4800 assay.Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types.Human papillomavirus DNA and mRNA prevalence and association with cervical cytological abnormalities in the Irish HIV population.Role of E6/E7 mRNA test in the diagnostic algorithm of HPV-positive patients showing ASCUS and LSIL: clinical and economic implications in a publicly financed healthcare system.Human papillomavirus mRNA and DNA testing in women with atypical squamous cells of undetermined significance: A prospective cohort study.Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers.Detection of cervical intraepithelial neoplasia with HPVE6/E7 mRNA among women with atypical squamous cells of unknown significance.Use of the NucliSENS EasyQ HPV assay in the management of cervical intraepithelial neoplasia.Prospective evaluation of E6/E7 mRNA detection by the NucliSENS Easy Q HPV assay in a stepwise protocol.Performance of ProEx C and PreTect HPV-Proofer E6/E7 mRNA tests in comparison with the hybrid capture 2 HPV DNA test for triaging ASCUS and LSIL cytology.Prognostic implication of high risk human papillomavirus E6 and E7 mRNA in patients with intraepithelial lesions of the cervix in relationship to age.E6/E7 proteins are potential markers for the screening and diagnosis of cervical pre-cancerous lesions and cervical cancer in a Chinese population.Performance of Aptima and Cobas HPV testing platforms in detecting high-grade cervical dysplasia and cancer.Separate analysis of human papillomavirus E6 and E7 messenger RNAs to predict cervical neoplasia progression.Comparison of oncogenic HPV type-specific viral DNA load and E6/E7 mRNA detection in cervical samples: results from a multicenter study.
P2860
Q27023127-A80E532B-A39D-4AD7-B57D-EA584906A378Q28087374-C0E048C9-8FB3-4DC4-A23B-417EAD0A8249Q33698073-ADE48DA9-9F82-49BA-8A20-A8DCD9719CF7Q34048160-9FE098AA-86DA-40C2-BD7A-CB42D0711738Q34205793-47F52EC8-D88B-4F92-99C7-A3B870396160Q34535660-1E094121-C235-48EE-8EF2-DEA03CD1D955Q34596772-E23ABE3E-EC80-45E8-9FD2-4DB9B73F2D13Q34608714-A2360202-30DA-468B-B00F-7B898E0A4814Q35140046-78FA7F84-4F07-4C0B-A16D-5638CB4058B8Q35530550-34CECD05-C96D-40B9-B3B4-2375C2D6ACD2Q35758717-AC0492B5-713C-4009-8D6C-85903023E312Q35975458-0C588919-9FDD-43B0-A243-AF9BDB036B0BQ36046119-0E4819EF-1C50-4FEC-A8B3-A35F18D181D4Q36118559-4E48B484-5CE8-43F9-809E-F399214F2148Q36118590-29604FC6-BD73-4256-AC3A-034D9C0B8847Q36311573-ECBCE755-685E-4047-AD08-973B3E2AB4F4Q36856284-0909CB23-4328-466D-99F1-7B9D8F9FB977Q37109872-7E0C66A4-F35D-46EF-BDBE-8E73608FAF66Q37177735-D117B798-FF55-48DB-9F33-D1B2B2C65F57Q37264271-F0B57CD4-9E95-4DF6-98B6-6F01A492DD14Q38123772-CC40E487-D3D9-4A9C-BD02-F612B2E8EEC2Q39122816-6F3B42E0-6F85-458D-9066-B01617E410F7Q39124983-E1230304-B15C-4706-9A7B-19C6A8C72A1BQ40744991-363CE76A-D889-4E75-8837-2801F5101A94Q40861259-CC075976-AD77-45C0-B855-3FCF0E4E432BQ41995526-B4D53FA2-BAC6-4128-B602-AAA0B0D38F40Q42252306-F3244DB5-6520-4A97-BC93-8FE36691F3ADQ42278781-203E3E06-C4B8-414D-A757-8CC544656EC1Q43524242-36842C2D-399E-43C5-9A71-5640808CA869Q44680676-797D721C-8B77-400B-A88F-A4D83EF00796Q47113153-5997988D-2311-43DB-A414-9E4CE5E405BBQ48336018-E1B09C94-8F20-4136-94CA-4A3859629BF1Q54269409-D0EE5DF0-A34E-437F-AD97-86151D276C96Q54277497-2A23B50B-C6C7-43C6-A6C2-79AF8514E2A6
P2860
Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Clinical performance of the Pr ...... en at risk of cervical cancer.
@ast
Clinical performance of the Pr ...... en at risk of cervical cancer.
@en
Clinical performance of the Pr ...... en at risk of cervical cancer.
@nl
type
label
Clinical performance of the Pr ...... en at risk of cervical cancer.
@ast
Clinical performance of the Pr ...... en at risk of cervical cancer.
@en
Clinical performance of the Pr ...... en at risk of cervical cancer.
@nl
prefLabel
Clinical performance of the Pr ...... en at risk of cervical cancer.
@ast
Clinical performance of the Pr ...... en at risk of cervical cancer.
@en
Clinical performance of the Pr ...... en at risk of cervical cancer.
@nl
P2093
P2860
P356
P1476
Clinical performance of the Pr ...... en at risk of cervical cancer.
@en
P2093
Adrian Lear
Christopher Giede
Dan Fontaine
Elias Bartellas
Francois Coutlee
Glen Holloway
James Bentley
Nicholas Escott
Prafull Ghatage
P2860
P304
P356
10.1128/JCM.00382-10
P407
P577
2010-06-23T00:00:00Z